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The cause of metabolic acidosis
To the Editor: As a case of ‘make your diagnosis’, Chang
et al.1 presented a case with metabolic acidosis. Although the
authors attributed the acid–base disorder of the case to
D-lactic acidosis, the laboratory ﬁndings would indicate
that the case had hyperchloremic acidosis in addition to
D-lactic acidosis. The case might also have had respiratory
alkalosis.
Having an anion gap of 21.1, the case would have an
anion-gap increase of 9.1–11.1 according to the indicated
reference value (10–12), although the value might need
adjustment by the plasma-albumin concentration and the
pH.2 The increase would reﬂect the sum of L-lactic acid and
D-lactic acid (9.4¼ 2.6þ 6.8) and indicate the metabolic
acidosis caused by these acids (mainly by D-lactic acid).
However, the case had the corrected bicarbonate of 13–15, the
sum of bicarbonate (3.9) and anion-gap increase, which is less
than the reference for bicarbonate (22–26). The low range of
corrected bicarbonate shows that the case had hyperchloremic
acidosis, which could have been caused by bicarbonate loss
due to intestinal malabsorption or renal tubular dysfunction,
because the decrease in corrected bicarbonate reﬂects the
increase in chloride.
For a decrease of bicarbonate (18.1–22.1), the expected
decrease of PaCO2 from its reference range (35–45) would be
18.1–26.5, and the predicted PaCO2 would be 8.5–26.9.
Having a PaCO2 of 9.6, a predicted value, the case would
have had an appropriate ventilatory response to metabolic
acidosis. However, considering the limit of respiratory
compensation for metabolic acidosis (a PaCO2 of 15–20),
the case might also have had respiratory alkalosis.
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Amino-terminal form of
parathyroid hormone in CKD
To the Editor: We read with great interest the review by
Souberbielle et al.1 on the practical issues of measuring
parathyroid hormone (PTH) in chronic kidney disease
patients. Here we would like to raise a few issues regarding
the amino-terminal form of PTH (N-PTH) that was brieﬂy
mentioned in their review.
As described in the article, N-PTH is detectable by the
whole PTH assay (third-generation assay) but is less well
reactive in ‘intact’ PTH assays (second-generation assays),
presumably due to a modiﬁcation in the 15–20 amino-acid
region. Therefore, in patients with N-PTH overproduction,
PTH values measured using the third-generation assays are
paradoxically higher than those measured using the second-
generation assays. Although not addressed in this review, it is
important to note that such an overproduction of N-PTH can
also occur in chronic kidney disease patients,2 making this
issue of critical importance in the evaluation of secondary
hyperparathyroidism.
Considering the potential impact of N-PTH on patient
care, one of the important issues is whether this molecule has
a biological effect on bone turnover. Although still unclear, it
is implicated that N-PTH has a signiﬁcant bioactivity, because
this molecule contains the very ﬁrst N-terminus that is
essential for interaction with the PTH/PTH-related protein
receptor. Indeed, most patients with N-PTH overproduction
or its corresponding reversed whole PTH/intact PTH ratio
(41) presented with severe parathyroid hyperplasia and
high-turnover bone disease despite low intact PTH levels.2,3 It
is also noteworthy that in one of such patients, treatment with
calcimimetics resulted in normalization of the reversed whole
PTH/intact PTH ratio.4 This ﬁnding underscores the
possibility that the calcium-sensing receptor may regulate
the secretion of not only 1–84 PTH but also this N-PTH
variant.
Although it is too early to draw a conclusion from these
data, they at least suggest that further insights into the
nature of N-PTH would provide useful information in
the management of secondary hyperparathyroidism. For
the precise evaluation of parathyroid function in chronic
kidney disease patients, further research on N-PTH is needed,
as well as a precise understanding of the characteristics of
each assay.
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